C Wu1, Q Tao. 1. Institute of Hepatology, The People's Hospital, Beijing Medical University, Beijing 100044, China.
Abstract
OBJECTIVES: To sequence E2/NS1 gene from genotype III Chinese isolates of hepatitis C virus (HCV) and analyze homology corresponding to the region of the reported isolates. METHODS: E2/NS1 gene derived from genotype III Chinese isolates of HCV was amplified by reverse transcripase-polymerase chain reaction (RT-PCR) and cloned into vector pcDNA3. Dideoxy chain termination methods were used to sequence E2/NS1 gene. RESULTS: E2/NS1 gene derived from genotype III Chinese isolates of HCV was cloned for the first time and named HC-W14. Identity of HC-W14 in nucleotide and putative amino acid to those of genotype III Japanese isolates of HCV were 88.37% and 89.29% respectively. Homology to that of non-type III isolates was relatively low. CONCLUSIONS: High variation existed in E2/NS1 region between genotype III and II Chinese isolates of hepatitis C virus. The variability of E2/NS1 gene should be taken into account in the development of vaccine against HCV in China.
OBJECTIVES: To sequence E2/NS1 gene from genotype III Chinese isolates of hepatitis C virus (HCV) and analyze homology corresponding to the region of the reported isolates. METHODS: E2/NS1 gene derived from genotype III Chinese isolates of HCV was amplified by reverse transcripase-polymerase chain reaction (RT-PCR) and cloned into vector pcDNA3. Dideoxy chain termination methods were used to sequence E2/NS1 gene. RESULTS: E2/NS1 gene derived from genotype III Chinese isolates of HCV was cloned for the first time and named HC-W14. Identity of HC-W14 in nucleotide and putative amino acid to those of genotype III Japanese isolates of HCV were 88.37% and 89.29% respectively. Homology to that of non-type III isolates was relatively low. CONCLUSIONS: High variation existed in E2/NS1 region between genotype III and II Chinese isolates of hepatitis C virus. The variability of E2/NS1 gene should be taken into account in the development of vaccine against HCV in China.